Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
W. Gradishar, D. Krasnojon, S. Cheporov, A. Makhson, G. Manikhas, A. Clawson, P. BharVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70725-0
File:
PDF, 61 KB
english, 2008